CD8A and neoplasm: ONP-302 pre-treatment led to a significant decrease in tumor growth in response to anti-PD-1 therapy (Figure 7E) concomitant with a significant increase in the percentage of CD8+ T cells that were IFN-ɣ+ and PD-1+ within the tumors (Figure 7F).